Search company, investor...

Igenica Biotherapeutics

igenica.com

Founded Year

2008

Stage

Asset Sale | AssetsPurchased

Total Raised

$85.73M

About Igenica Biotherapeutics

Igenica is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica's integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients.

Headquarters Location

863 Mitten Rd Suite 102

Burlingame, California, 94010,

United States

650-697-4900

Missing: Igenica Biotherapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Igenica Biotherapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Igenica Biotherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Igenica Biotherapeutics is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Igenica Biotherapeutics Patents

Igenica Biotherapeutics has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/6/2014

1/25/2022

Monoclonal antibodies, Experimental cancer drugs, Monoclonal antibodies for tumors, Immunology, Clusters of differentiation

Grant

Application Date

6/6/2014

Grant Date

1/25/2022

Title

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Monoclonal antibodies for tumors, Immunology, Clusters of differentiation

Status

Grant

Latest Igenica Biotherapeutics News

Igenica Biotherapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250

Aug 2, 2018

18:39 EDT 2 Aug 2018 | BioPortfolio Reports Summary Igenica Biotherapeutics Inc Igenica is a provider of antibody drug conjugate services. The company's product candidates includes IGN523, a humanized monoclonal antibody used to multiple hematologic and solid tumors. It offers IGN786, which is used novel target such as SAIL and IGN381, a novel approach to immunotherapy targeting an immune checkpoint target. Igenica works in collaboration with academic institutions, government agencies and pharmaceutical companies. The company offers services to advance technology platforms and novel therapeutic programs. It utilizes its proprietary ADC platform to accelerate the development and delivery of therapies. Igenica is headquartered in Burlingame, California, the US. Igenica Biotherapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Igenica Biotherapeutics Frequently Asked Questions (FAQ)

  • When was Igenica Biotherapeutics founded?

    Igenica Biotherapeutics was founded in 2008.

  • Where is Igenica Biotherapeutics's headquarters?

    Igenica Biotherapeutics's headquarters is located at 863 Mitten Rd, Burlingame.

  • What is Igenica Biotherapeutics's latest funding round?

    Igenica Biotherapeutics's latest funding round is Asset Sale.

  • How much did Igenica Biotherapeutics raise?

    Igenica Biotherapeutics raised a total of $85.73M.

  • Who are the investors of Igenica Biotherapeutics?

    Investors of Igenica Biotherapeutics include Pierre Fabre, 5AM Ventures, The Column Group, Third Rock Ventures and OrbiMed Advisors.

  • Who are Igenica Biotherapeutics's competitors?

    Competitors of Igenica Biotherapeutics include Aquinox Pharmaceuticals, Forte Biosciences, Ikaria, MabVax Therapeutics, Sopherion and 10 more.

Compare Igenica Biotherapeutics to Competitors

S
Sopherion

Sopherion is a therapeutics platform company initially focused on cancer.

N
Neomics

Neomics is a drug discovery and diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to aminoacyl RNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.

N
NanoMedica

NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.

E
Eximias

Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

F
Falcon Genomics

Falcon Genomics, Inc. is focused on functional genomics as a tool for cancer diagnostics and therapeutics.

P
Progression Therapeutics

Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.